Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 9/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21276202 | 0.93 | USP2 (0.56) | USP2CYP3A4CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL21276211 | 0.89 | FAAH (0.56) | USP2CYP3A4CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL21276209 | 0.88 | USP2 (0.49) | USP2CYP3A4CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL21276272 | 0.88 | USP2 (0.49) | USP2CYP3A4CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL21276150 | 0.87 | USP2 (0.51) | USP2CYP3A4CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL21276223 | 0.85 | MGLL (0.49) | USP2CYP3A4CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL21276187 | 0.84 | MGLL (0.52) | — | |
| SCHEMBL21276161 | 0.84 | GPR52 (0.46) | ALDH1A1 | |
| SCHEMBL21276210 | 0.81 | FAAH (0.58) | USP2CYP3A4CYP2D6SMN1; SMN2TSHR | |
| SCHEMBL21257967 | 0.81 | CYP3A4 (0.51) | USP2CYP3A4CYP2D6TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385057-B2 | Pyrazole compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385057-B2 | Pyrazole compounds and methods of making and using same | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180327410-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327410-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | FAAH, FAAH2, MGLL | USP2 2128/4885CYP3A4 193/4885CYP2D6 114/4885 |
| US-10385057-B2 | Pyrazole compounds and methods of making and using same | FAAH, FAAH2, MGLL | USP2 2128/4885CYP3A4 193/4885CYP2D6 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.